



# HEARTS

IN THE AMERICAS  
Regional Workshop

## WHO DIABETES Guidelines and Diabetes Module in PEN

Gojka Roglic

World Health Organization

Switzerland



# WHO guidance on diabetes diagnosis and management



**Package of Essential  
Noncommunicable (PEN) Disease  
Interventions for  
Primary Health Care  
in Low-Resource Settings**



Report of a World Health Organization Consultation

## Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus<sup>☆</sup>

Executive summary

chronic hyperglycaemia and disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both [1]. The long-term relatively



## Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications

Report of a WHO Consultation

Part 1: Diagnosis and Classification of  
Diabetes Mellitus



World Health Organization  
Department of Noncommunicable Disease Surveillance  
Geneva

**Guidelines on second-and third-line  
medicines and type of insulin for  
the control of blood glucose levels  
in non-pregnant adults with  
diabetes mellitus**





**Training Manual**  
**WHO Package of Essential NCD Interventions (PEN)**  
**Part-II - Protocols**

DRAFT FOR FIELD TRIAL



# What is diabetes ?

- Diabetes is a group of metabolic disorders characterized by the presence of hyperglycaemia in the absence of treatment.
- Diabetes occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces
- The long-term specific complications of diabetes include retinopathy, nephropathy and neuropathy



# Main types of diabetes

- Type 1 diabetes
  - characterized by deficient insulin production
  - requires daily administration of insulin for survival
- Type 2 diabetes
  - The most common type of diabetes (>90%)
  - Combination of resistance to insulin action and an inadequate insulin secretory response due to  $\beta$ -cell dysfunction
  - Insulin is not required for survival, but often needed it for controlling blood glucose levels
- Gestational diabetes
  - Gestational diabetes is hyperglycaemia with blood glucose values above normal but below those diagnostic of diabetes, occurring during pregnancy



# Steps of management of diabetes in a primary care setting

## Assess

- Risk factors
- Symptoms
- Signs
- Tests

## Diagnose

- Establish a diagnosis

## Treat

- Non pharma
- Pharma
- Refer
- Emergencies

## Follow-up

- Compliance
- Check for complications



# Assess

## Risk factors/markers for diabetes

- Overweight/obesity
- Physical inactivity
- Diabetes in first degree relatives
- History of gestational diabetes
- Cardiovascular disease, hypertension

## Symptoms

- Polyuria (excessive passing of urine)
- Polydipsia (excessive thirst)
- Unexplained weight loss
- Polyphagia (excessive hunger)
- Vision changes
- Fatigue

Majority of cases have no clinical symptoms and can present with complications



# Diagnostic criteria for diabetes

Measurement	Diagnostic cut-off	Comments
<b>Fasting* venous or capillary** plasma glucose</b>	<b>≥7.0 mmol/l (126 mg/dl)</b>	Least costly but difficulties with ensuring a fasting state
<b>2-hour post-load venous plasma glucose</b>	≥11.1 mmol/l (200 mg/dl)	Standard method, but cumbersome and costly
<b>2-hour post-load capillary** plasma glucose</b>	≥12.2 mmol/l (220 mg/dl)	Cumbersome and costly, difficulties with ensuring a fasting state
<b>Random plasma glucose</b>	≥11.1 mmol/l (200 mg/dl)	<i>Least sensitive</i> test, to be used in the presence of symptoms
<b>HbA1c***</b>	6.5% (48 mmol/l)	Does not require the fasting state but more costly

*\*overnight fast of 8-14 hours; \*\*if laboratory measurement is not available, point of care devices can be used (they report glucose values in capillary plasma); \*\*\* plasma glucose is preferred in people with symptoms who are suspected of having type 1 diabetes*





# Treatment principles

## Non-pharmacological

A **healthy diet**, maintaining **normal body weight** and regular **physical activity** are the **mainstay** of diabetes management

## Pharmacological

- **Metformin** is the recommended **initial treatment** for people who do not achieve the desired glycaemic control with diet and physical activity.
- **Sulfonylurea** can be used as initial ( first-line) treatment **when metformin is contraindicated or not tolerated**
- **Add sulfonylurea** when metformin fails
- **Add human insulin** if treatment with metformin and sulfonylurea fails

## Indications for referral

If control is not achieved even after 3 months despite adherence to medication, healthy diet and physical activity



# Whom to test ?

(WHO Diabetes protocol 2018)

**TEST ADULTS** who have symptoms of diabetes with fasting or random plasma glucose (FPG or RPG),

Test adults who are 40+ years old with BMI >25 with FPG (asymptomatic)

FPG  $\geq 7$  mmol/l and  $< 18$  mmol/l<sup>‡</sup>  
or RPG  $\geq 11.1$  mmol/l  
and  $< 18$  mmol/l<sup>‡</sup>

<sup>‡</sup> FPG  $\geq 126$  mg/dl and  $< 325$  mg/dl or  
RPG  $\geq 200$  mg/dl and  $< 325$  mg/dl

FPG/RPG  $> 18$  mmol/l  
( 325 mg/dl)

TEST urine ketones

In **asymptomatic** people, it is recommended to **repeat** testing to confirm the diagnosis, preferably with the same test, as soon as practicable on a subsequent day



# Control of blood glucose

FPG  $\geq 7$  mmol/l and  $< 18$  mmol/l<sup>†</sup>  
or RPG  $\geq 11.1$  mmol/l  
and  $< 18$  mmol/l<sup>†</sup>

Counsel on diet and  
physical activity

**REVIEW IN 3 MONTHS**  
If goal not achieved  
**BEGIN METFORMIN**  
500 mg once daily.  
Counsel on diet and physical  
activity and adherence  
at ALL visits

**REVIEW IN 3 MONTHS**  
If goal not achieved increase  
dose to 1000 mg 1x daily

**REVIEW IN 3 MONTHS**  
If goal not achieved,  
**ADD** gliclazide 80 mg 1x daily.  
Counsel on hypoglycaemia at all  
subsequent visits


**REVIEW IN 3 MONTHS**  
If goal not achieved increase  
dose to 80 mg 2x daily

**REVIEW IN 3 MONTHS**  
If goal not achieved, despite  
adherence to medication,  
healthy diet and physical  
activity, **REFER** to higher-level  
health care facility for starting  
insulin\*

<sup>†</sup> FPG  $\geq 126$ mg/dl and  $< 325$ mg/dl or  
RPG  $\geq 200$ mg/dl and  $< 325$ mg/dl



# Management in presence of ketonuria



# TREATMENT GOAL IN DIABETES

HbA1c of 7.0%

**OR**

Fasting PG value of 7.0 mmol/l ( 126mg/dl)

**AND ( if measurement feasible)**

Postprandial PG value of 9.0 mmol/l (160 mg/dl)



# TREATMENT GOAL IN DIABETES

HbA1c of 7.0%

OR

Consider less stringent glycaemic control in patients with frequent severe hypoglycaemia, advanced complications, serious comorbidities and/or limited life expectancy.

Postprandial PG value of 9.0 mmol/l (160 mg/dl)



# Follow-up

## Check for complications

- Measure **blood pressure** at every visit
- REFER for dilated-pupil **retinal exam** upon diagnosis, and every two years thereafter
- Examine **feet for ulcers** at every visit. REFER to higher level of care if ulcer present
- Assess risk of **lower limb** amputation annually. REFER to higher level of care if ulcer present or pulse absent
- Test for **proteinuria** annually. REFER to higher level of care if positive.



# Precautions with antidiabetic drugs

## Metformin is contraindicated in

- people with chronic kidney disease (estimated glomerular filtration rate (eGFR)  $<45$  ml/minute/1.73m<sup>2</sup>)
- liver disease
- cardiac/respiratory insufficiency
- alcohol abuse
- history of lactic acidosis



## Glibenclamide is not recommended in

- people aged 60 years or older
- In patients for whom hypoglycaemia is a concern (people who are at risk of falls, people who have impaired awareness of hypoglycaemia, people who live alone)
- people who drive or operate machinery as part of their job





# Macrovascular complications

Patients with diabetes are at a higher risk of:

- Coronary heart disease
- Heart failure
- Cerebrovascular disease
- Peripheral vascular diseases



# Management of CVD risk factors in diabetes (hypertension)

## Blood pressure control

- Blood pressure lowering in people with diabetes reduces the risk of microvascular and macrovascular complications
- **Thiazide diuretics** and **angiotensin-converting enzyme (ACE) inhibitors** are **recommended**
- Target should be to achieve a target blood pressure < 130/80 mmHg.
- If this is not achievable, refer to a higher level of care.



# Management of CVD risk factors in diabetes (lipid control)

## Lipid control

- Some lipid profile improvement can be achieved with a healthy diet and physical activity.
- *Statins* can reduce the risk of CVD events in people with diabetes.

## Antiplatelet treatment

- Use antiplatelet treatment only for secondary prevention of CVD events.
- 75-100 mg of acetylsalicylic acid daily is recommended to all people with diabetes who have survived a CVD event and have no history of major bleeding



# Acute complications of diabetes

**Hypoglycaemia**  
**Hyperglycaemia**



# Hypoglycaemia

- Hypoglycaemia (abnormally low blood glucose) is a frequent complication in patients receiving sulfonylurea or insulin.
- There is no universally agreed plasma glucose cut-off point for hypoglycaemia as symptoms and signs can occur at different thresholds.
- It is most frequently defined at **plasma glucose of <3.9 mmol/l (70 mg/dl)** when it **should be managed even if there are no symptoms and signs.**
- **Severe hypoglycaemia** (plasma glucose <50 mg/dl or 2.8 mmol/l) or appearance of signs
- It can cause loss of consciousness and coma and is potentially life-threatening



# Assess for hypoglycaemia

## Risk factors

- Skipping meals
- Physical activity more intense than usual
- Alcohol ingestion
- Medicine dosage too high

## Symptoms and signs

- Hunger, anxiety, confusion, trembling
- Sweating, headache, seizures
- Palpitations
- Pallor, stupor, ataxia, paraesthesia
- Coma



# Management of hypoglycaemia – conscious patient

If the patient is able to eat and drink:

- Give oral carbohydrate that contains 15-20 g of rapidly absorbing forms of glucose (sugar-sweetened soft drink, 1-2 teaspoons of sugar, 5-6 hard candy, cup of milk)
- Repeat the treatment if hypoglycaemia persists after 15 minutes
- If rapidly absorbing glucose is not available, any foods containing carbohydrate can be given ( e.g. bread, rice, potato)
- Follow by a small meal



# Management of hypoglycaemia-unconscious patient

If patient is Unconscious,

- If plasma glucose  $\leq 2.8$  mmol/l ( 50mg/dl ) and in those unable to eat or ingest drink – give hypertonic glucose (dextrose) intravenously (20 – 50 ml of 50% glucose over 1-3 minutes).
- If this concentration is not available, substitute with any hypertonic glucose solution
- Food should be provided as soon as the patient is able to ingest food safely.
- Adjust medication if necessary.
- Educate the patient about conditions leading to hypoglycaemia.





# Hyperglycaemic emergencies

- **Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycaemic state (HHS) are life-threatening conditions**
- **Severe hyperglycaemia-**
  - Plasma glucose  $>18$  mmol/l (325 mg/dl) and
  - Urine ketone 2+ or signs and
  - Symptoms of severe hyperglycaemia



# Symptoms and signs of severe hyperglycaemia (DKA and HHS)

- Nausea, vomiting and abdominal pain
- Severe cases of DKA can present with Kussmaul's breathing\*
- Changes in sensorium range from alertness to stupor or coma, depending on the severity
- Patients with **HHS typically present in stupor or coma**

*\*Kussmaul breathing: Air hunger, or rapid, deep, and laboured breathing characteristic of patients with acidosis*



# Management of hyperglycaemic emergencies

- DKA or HHS should be suspected in every ill patient with hyperglycaemia
- Refer to hospital all patients with plasma glucose levels  $\geq 18$  mmol/l (325 mg/dl) and all patients with suspected DKA or HHS
- **Infuse isotonic saline (0.9% NaCl) at a rate of 1000 ml in the first 2 hours, continue with 1000ml every 4 hours until reaching hospital.**
- Hyperglycaemia slows gastric emptying and oral rehydration might not be effective, even in patients who are not vomiting

Correction of dehydration is the critical first step for transport.



# Specific Long term Complications of Diabetes

- Diabetic retinopathy
- Diabetic nephropathy
- Diabetic neuropathy
- Diabetic foot



# Diabetic retinopathy

## Definition

Diabetic retinopathy is a highly specific vascular complication of diabetes and among the leading causes of blindness

## Risk factors for diabetic eye changes

- duration of diabetes
- glycaemic control
- hypertension
- diabetic kidney disease
- dyslipidaemia

## Signs and symptoms of diabetic eye changes

- Vision-threatening retinopathy and macular changes may be *asymptomatic*
- Vision loss occurs at advanced stages.

## Diagnosis

- Presence of specific retinal lesions and macular edema on fundus examination after pupil dilation



# Recommendations for early detection of diabetic retinopathy

- People with type 2 diabetes should be screened for retinopathy by a trained person *upon diagnosis and every 2 years thereafter*
  - Visual acuity
  - Direct or indirect ophthalmoscopy or retinal fundus photography, after dilating the pupils
- Patients reporting vision loss at any visit and those who have not had a retinal exam in more than 2 years should be referred to an ophthalmologist.
- Referral to an ophthalmologist is recommended if screening by a trained person is not available in primary care.



# Diabetic nephropathy

## Definition

Diabetic nephropathy is a clinical syndrome defined by persistent albuminuria\* characterized by a relentless decline in glomerular filtration rate (GFR), raised arterial blood pressure and high risk of CVD & death

## Risk factors for kidney changes

- genetic susceptibility
- poor glycaemic control
- elevated blood pressure

## Signs and symptoms of diabetic nephropathy

- The first symptom of diabetic nephropathy is usually **peripheral edema**, but this occurs at a very late stage
- The first clinical sign is moderately increased **urine albumin** excretion (albuminuria: 30–300 mg/24 h, or an albumin/creatinine ratio 30–300 mg/g, or dipstick trace/1+).
- Severe albuminuria is albumin/creatinin ratio >300mg/g (dipstick 1+/2+ )
- Glomerular filtration rate (GFR) <60ml/min/1.73m<sup>2</sup>

*\*albuminuria in at least 2 of 3 consecutive samples  $\geq$ 3 months apart*



## Recommendations for early detection of diabetic nephropathy

- ***Once a year monitor*** the albumin/creatinine ratio in a spot urine sample and serum creatinine for estimating glomerular filtration rate ( eGFR)
- If measurement of urine albumin/creatinine ratio is not available, test for proteinuria (preferably with strips that specifically measure lower concentrations of albumin).
- Refer to higher level: patients with moderate or severe albuminuria, patients with  $GFR < 60 \text{ ml/min/1.73m}^2$
- Maintain blood pressure levels at  $< 130/80 \text{ mmHg}$  with a thiazide diuretic and an ACE-inhibitor
- Modify other major CVD risk factors ( dyslipidaemia, smoking)





# Diabetic neuropathy

## Definition

- Nerve damage or degeneration in diabetes is a group of disorders with diverse clinical manifestations like sensory and disorders of autonomic nervous system.

## Risk factors

- Duration of diabetes, Poor glycaemic control
- Age, Hypertension , Obesity

## Signs and symptoms of diabetic neuropathy

Peripheral neuropathy	Autonomic neuropathy
<ul style="list-style-type: none"><li>• Sensory loss</li><li>• Unpleasant sensation of burning, pain</li><li>• Tingling or numbness</li></ul>	<ul style="list-style-type: none"><li>• Hypoglycaemia</li><li>• Orthostatic hypotension</li><li>• Resting tachycardia</li><li>• Diarrhoea, constipation and fecal incontinence</li><li>• Erectile dysfunction</li><li>• Urinary incontinence and bladder dysfunction</li></ul>




# Recommendations for management of diabetic neuropathy

- Specific treatment for the underlying nerve damage is not available
- If possible, exclude causes of peripheral neuropathy other than diabetes (alcohol, chemotherapy, vitamin B12 deficiency, hypothyroidism, renal disease, malignancies, HIV infection)
- Refer patients with painful peripheral neuropathy to specialized care for pharmacological management of pain
- Refer patients with suspected autonomic neuropathy to specialized care
- **Improve glycaemic and blood pressure control**



# Foot problems in diabetes

- **Diabetic foot** is one of the most common, costly and severe complications of diabetes
- A diabetic foot ulcer is a localised injury to the skin and/or underlying tissue below the ankle.
- Most diabetic foot ulcers are caused by *trauma* from inappropriate footwear and/or *walking barefoot with insensitive feet*.
- Combined with reduced blood flow, neuropathy in the feet increases the chance of foot ulcers, infection and eventual need for limb amputation.



# Symptoms of diabetic foot

- Patients can present with symptoms and signs of peripheral neuropathy and/or peripheral artery occlusion and other risk factors for amputation
- Symptoms are :
  - Intermittent claudication - pain in calves when walking, usually disappears in rest ( occlusion in peripheral arteries)
  - symptoms of neuropathy

**The absence of symptoms does not exclude diabetic foot problems.**



# Assessment and management of risk of active foot problems

## Examination of the feet

- Remove the patient's shoes, socks, dressings and bandages
- *Check for Peripheral neuropathy -*
  - **Pressure perception** testing with 10g Semmes-Weinstein monofilament and
  - *At least one other test of **sensation** ( 128Hz tuning fork vibration / cotton wisp /pin prick – see images) and*
  - **Achilles tendon reflexes**



# Monofilament test

Sensory examination should be carried out in a quiet and relaxed setting.

- First apply the monofilament on the patient's hands (or elbow or forehead) so that she or he knows what to expect.
- The patient must not be able to see whether or where the examiner applies the filament .
- The three sites to be tested on both feet are indicated in Figure
- The total duration– skin contact and removal of the filament should be approx. 2 secs.
- Apply the filament along the perimeter of, **not on an ulcer site callus or necrotic tissue.**
- Do not allow the filament to slide across the skin or make repetitive contact at the test site.

**Figure a:  
Sites for  
monofilament test**



# Monofilament test (contd)


- Apply the monofilament perpendicular to the skin surface. Apply sufficient force to cause the filament to bend or buckle.
- Press the filament to the skin and ask the patient whether they feel the pressure applied (Yes/No)
- Next, ask where they feel the pressure (right foot / left foot)
- Repeat this application twice at the same site but alternate this with one “mock” application in which no filament is applied
- So, in total **three questions per site** should be asked



# Tuning fork test

- Sensory examination should be carried out in a quiet and relaxed setting.
- First, apply the tuning fork on the patient's wrist (or elbow or clavicle) so that he or she knows what to expect
- The patient must not be able to see whether or where the examiner applies the tuning fork.
- The tuning fork is applied on a bony part on the dorsal side of the distal phalynx of the first toe
- The tuning fork should be applied perpendicularly with constant pressure (fig d)
- Repeat this application twice but alternate this with at least one “mock” application in which the tuning fork is not vibrating.


Figure d :  
Site for tuning fork test





# Interpretation of Tuning fork test

- The test is **positive** if the patient correctly answers at least two out of three applications
- The test is **negative** with two out of three incorrect answers, i.e patient is “**at risk for ulceration**”
- If the patient is unable to sense the vibrations on the big toe the test is repeated more proximally (malleolus)



# Palpation of arteries

## Palpation of dorsal pedis:

- Feel in the middle of the dorsum of the foot just lateral to the tendon of extensor hallucis longus (extensor tendon of the great toe)



## Posterior tibial artery:

- Midway between medial malleolus and calcaneal tendon



# Signs for classifying a patient's risk for developing diabetic foot problems

Palpation of tibial posterior and dorsal pedal artery pulse

Presence of current or previous (healed) ulcer

Previous amputation

Presence of callus

Presence of deformity: claw toes, hammer toes, bony prominences; limited joint mobility

Presence of Charcot arthropathy : redness, warmth, swelling or deformity, particularly if skin is intact

Signs of infection or inflammation: at least two of redness, warmth, induration, tenderness, purulent secretion

Signs of gangrene



## Stratification of risk for developing diabetic foot problems

Risk level	Low risk	Moderate risk	High risk	Active foot problem
<b>Features</b>	No risk factor except <i>callus alone</i>	Any of: <ul style="list-style-type: none"> <li>•deformity</li> <li>•neuropathy</li> <li>•non-critical limb ischaemia</li> </ul>	Any of: <ul style="list-style-type: none"> <li>•previous ulcer</li> <li>•previous amputation</li> <li>•neuropathy with non-critical limb ischaemia</li> <li>•neuropathy with callus and/or deformity</li> <li>•non-critical limb ischaemia with callus and/or deformity</li> </ul>	Any of: <ul style="list-style-type: none"> <li>•Ulcer</li> <li>•Spreading infection</li> <li>•Critical limb ischaemia</li> <li>•Gangrene</li> <li>•Suspicion of acute Charcot arthropathy</li> <li>•Unexplained red swollen foot</li> </ul>
<b>Action</b>	Assess Annually	Assess every 3-6 months	Assess every 1-3 months	Urgent referral





# Recommended actions for foot deformities


- Removal of callus ( or refer if not feasible)
- Protecting or draining blisters
- Treatment of ingrown and thickened nails( or refer if not feasible)
- Antifungal treatment for fungal infections
- Patients with **gross foot deformities** and/or absent peripheral pulses should be referred for further evaluation.




# COMMON DIABETIC FOOT PROBLEMS



BUNION




CALLUS




CORN (HAMMER TOE)



TOENAILS



DRY SKIN



ULCER

*Konstantin*




# Counselling on foot care

- ✓ Examine the feet daily, including between the toes
- ✓ Avoid walking barefoot, in thin-soled footwear or in socks only, both at home and outside
- ✓ Wash feet daily with water temperature below 37°C and dry them well, especially between the toes
- ✓ Lubricate skin with emollients, but not between the toes
- ✓ Cut toenails straight across.
- ✓ Wear socks without seams, not wear tight or knee-high sock and change socks daily
- ✓ Do not wear shoes that are too tight, have rough edges or uneven seams; the inside should be 1-2 cm longer than the foot
- ✓ Inspect shoes inside before putting them on
- ✓ Do not remove corns and calluses, including with chemical agents or plasters



<https://www.who.int/diabetes/en/>

- Includes Activities and Case studies





Thank you

**roglicg@who.int**